SQZ Biotechnologies Co. (SQZ): Price and Financial Metrics

SQZ Biotechnologies Co. (SQZ): $7.33

-0.30 (-3.93%)

POWR Rating

Component Grades













Add SQZ to Watchlist
Sign Up

Industry: Biotech


of 453

in industry


  • Sentiment is the dimension where SQZ ranks best; there it ranks ahead of 67.95% of US stocks.
  • The strongest trend for SQZ is in Stability, which has been heading up over the past 163 days.
  • SQZ ranks lowest in Momentum; there it ranks in the 4th percentile.

SQZ Stock Summary

  • SQZ Biotechnologies Co's stock had its IPO on October 30, 2020, making it an older stock than just 0.59% of US equities in our set.
  • SQZ's price/sales ratio is 11.76; that's higher than the P/S ratio of 87.43% of US stocks.
  • SQZ Biotechnologies Co's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -64.29%, greater than the shareholder yield of only 6.65% of stocks in our set.
  • Stocks that are quantitatively similar to SQZ, based on their financial statements, market capitalization, and price volatility, are GSIT, LPTX, TMDI, PLRX, and MGNX.
  • Visit SQZ's SEC page to see the company's official filings. To visit the company's web site, go to www.sqzbiotech.com.

SQZ Valuation Summary

  • SQZ's EV/EBIT ratio is -3.5; this is 111.95% lower than that of the median Healthcare stock.
  • Over the past 44 weeks, SQZ's price/earnings ratio has gone up 2.4.
  • Over the past 44 weeks, SQZ's EV/EBIT ratio has gone up 2.6.

Below are key valuation metrics over time for SQZ.

Stock Date P/S P/B P/E EV/EBIT
SQZ 2021-08-31 20.1 2.4 -5.8 -3.5
SQZ 2021-08-30 20.1 2.4 -5.8 -3.6
SQZ 2021-08-27 20.4 2.5 -5.9 -3.6
SQZ 2021-08-26 19.2 2.3 -5.5 -3.3
SQZ 2021-08-25 18.3 2.2 -5.3 -3.0
SQZ 2021-08-24 18.2 2.2 -5.3 -3.0

SQZ's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SQZ has a Quality Grade of C, ranking ahead of 53% of graded US stocks.
  • SQZ's asset turnover comes in at 0.082 -- ranking 279th of 680 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows SQZ's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.082 1 -1.099

SQZ Price Target

For more insight on analysts targets of SQZ, see our SQZ price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $37.67 Average Broker Recommendation 1.2 (Strong Buy)

SQZ Stock Price Chart Interactive Chart >

Price chart for SQZ

SQZ Price/Volume Stats

Current price $7.33 52-week high $29.34
Prev. close $7.63 52-week low $6.90
Day low $7.11 Volume 44,900
Day high $7.63 Avg. volume 69,200
50-day MA $10.55 Dividend yield N/A
200-day MA $12.58 Market Cap 205.73M

SQZ Biotechnologies Co. (SQZ) Company Bio

SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. It operates through SQZ Cell Therapy Platform, which uses membrane disruption to deliver material into cells. The company was founded by Robert S. Langer Jr., Klavis F. Jensen, Agustin Lopez Marquez, and Armon Sharei in March 2013 and is headquartered in Watertown, MA.

SQZ Latest News Stream

Event/Time News Detail
Loading, please wait...

SQZ Latest Social Stream

Loading social stream, please wait...

View Full SQZ Social Stream

Latest SQZ News From Around the Web

Below are the latest news stories about SQZ Biotechnologies Co that investors may wish to consider to help them evaluate SQZ as an investment opportunity.

SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors

WATERTOWN, Mass., January 24, 2022--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for SQZ-eAPC-HPV, authorizing the company to proceed with initiating a Phase 1/2 clinical trial of the novel cell therapy candidate. The company plans to initiate its COMMANDER-001 Phase 1/2 clinical trial of

Yahoo | January 24, 2022

Bangor Savings Bank Buys Vanguard Intermediate-Term Government Bond ETF, Global Payments Inc, ...

Bangor, ME, based Investment company Bangor Savings Bank (Current Portfolio) buys Vanguard Intermediate-Term Government Bond ETF, Global Payments Inc, Vanguard Tax-Exempt Bond ETF, International Business Machines Corp, Newell Brands Inc, sells Consumer Discretionary Select Sector SPDR, BP PLC, Philip Morris International Inc, Vanguard Intermediate-Term Corporate Bond ETF, iShares ESG Aware U.S.

Yahoo | January 20, 2022

SQZ Biotechnologies Announces Healthcare Industry Leader John Maraganore, Ph.D. Joining as Strategic Advisor

WATERTOWN, Mass., January 06, 2022--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that John Maraganore, Ph.D., founding CEO of Alnylam Pharmaceuticals, has joined the company as a strategic advisor.

Yahoo | January 6, 2022

SQZ: Preliminary Results Feature Patient 17

By John Vandermosten, CFA NYSE:SQZ READ THE FULL SQZ RESEARCH REPORT ESMO-IO Preliminary Results and Webcast/Conference Call SQZ Biotechnologies Company (NYSE:SQZ) hosted a webcast and conference call on December 9, 2021 to discuss updates to SQZ-PBMC-HPV-101 program at ESMO 1 Immuno-Oncology Congress 2021. SQZ-PBMC-HPV-101 is the company’s antigen presenting cell (APC) lead program. Jong Chul

Yahoo | December 16, 2021

SQZ Biotechnologies Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient

WATERTOWN, Mass., December 09, 2021--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today presented interim results from the highest-dose cohort of its ongoing Phase 1/2 clinical trial of lead Antigen Presenting Cell (APC) therapy candidate targeting Human Papillomavirus positive (HPV16+) solid tumors at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress. Of the five patients in this cohort eva

Yahoo | December 9, 2021

Read More 'SQZ' Stories Here

SQZ Price Returns

1-mo -26.33%
3-mo -45.70%
6-mo -39.42%
1-year -71.60%
3-year N/A
5-year N/A
YTD -17.92%
2021 -69.19%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7013 seconds.